E-LIB Suche - Ergebnisse für: Ray Coquard, I.L.

1

34O ROCSAN: A multicentric randomized phase II/III evaluati..:

Ray-Coquard, I.L. ; Bellesoeur, A. ; Fabbro, M....
ESMO Open. 9 (2024) - p. 103534 , 2024

Link: https://doi.org/10.1016/..

2

59MO COTESARC – A multicentre, phase I-II clinical trial ev..:

Dufresne, A. ; Brahmi, M. ; Cropet, C....
ESMO Open. 9 (2024) - p. 102449 , 2024

Link: https://doi.org/10.1016/..

3

Atezolizumab plus bevacizumab and chemotherapy for metastat..:

Oaknin, Ana ; Gladieff, Laurence ; Martínez-García, Jerónimo...
The Lancet. 403 (2024) 10421 - p. 31-43 , 2024

Link: https://doi.org/10.1016/..

4

PARP inhibition with rucaparib alone followed by combinatio..:

Kristeleit, Rebecca ; Leary, Alexandra ; Oaknin, Ana...
British Journal of Cancer. , 2024

Link: https://doi.org/10.1038/..

5

Spatial Profiling of Ovarian Carcinoma and Tumor Microenvir..:

Yaniz-Galende, Elisa ; Zeng, Qinghe ; Bejar-Grau, Juan F....
Clinical Cancer Research. 30 (2024) 13 - p. 2790-2800 , 2024

Link: https://doi.org/10.1158/..

6

59P Real-world effectiveness of niraparib in recurrent ovar..:

Hanvic, B. ; Macouillard, P. ; Gladieff, L....
ESMO Open. 9 (2024) - p. 103566 , 2024

Link: https://doi.org/10.1016/..

7

Impact of molecular testing on the surgical management of a..:

Colombo, Pierre-Emmanuel ; Taoum, Christophe ; Fabbro, Michel...
Critical Reviews in Oncology/Hematology. 202 (2024) - p. 104469 , 2024

Link: https://doi.org/10.1016/..

8

55O IMADGIST: A randomized study of 6 vs 3 years of adjuvan..:

Le Cesne, A. ; Chabaud, S. ; Bouche, O....
ESMO Open. 9 (2024) - p. 102445 , 2024

Link: https://doi.org/10.1016/..

9

Neoadjuvant and adjuvant pembrolizumab in advanced high-gra..:

Ray-Coquard, Isabelle L. ; Savoye, Aude-Marie ; Schiffler, Camille...
Nature Communications. 15 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

10

19P Long-term fatigue after treatments for non-epithelial o..:

Dubot, C. ; Ray-Coquard, I.L. ; Pautier, P....
ESMO Open. 9 (2024) - p. 102558 , 2024

Link: https://doi.org/10.1016/..

11

Discontinuation versus continuation of imatinib in patients..:

Blay, Jean-Yves ; Devin, Quentin ; Duffaud, Florence...
The Lancet Oncology. , 2024

Link: https://doi.org/10.1016/..

12

82MO European multi-disciplinary tumor boards within the EU..:

Bergamini, A. ; Joneborg, U. ; Marquina, G....
ESMO Open. 9 (2024) - p. 103542 , 2024

Link: https://doi.org/10.1016/..

13

Long term survival in adult osteosarcoma patients treated w..:

Blay, Jean-Yves ; Penel, Nicolas ; Toulmonde, Maud...
European Journal of Cancer. 208 (2024) - p. 114228 , 2024

Link: https://doi.org/10.1016/..

14

Improved nationwide survival of sarcoma patients with a net..:

Blay, J.Y. ; Penel, N. ; Valentin, T....
Annals of Oncology. 35 (2024) 4 - p. 351-363 , 2024

Link: https://doi.org/10.1016/..

15

Should all advanced BRCA-mutated patients in response to fi..:

Turinetto, M. ; Ray-Coquard, I. ; Gourley, C.
ESMO Open. 9 (2024) 5 - p. 102983 , 2024

Link: https://doi.org/10.1016/..